Atrion (NASDAQ:ATRI) Stock Rating Lowered by StockNews.com

Atrion (NASDAQ:ATRI) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Monday.

Atrion Stock Performance

Shares of Atrion stock opened at $405.29 on Monday. Atrion has a 52-week low of $274.98 and a 52-week high of $643.48. The stock’s 50-day simple moving average is $402.59 and its 200 day simple moving average is $364.60. The stock has a market capitalization of $713.31 million, a P/E ratio of 36.74 and a beta of 0.60.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%. The firm had revenue of $43.58 million for the quarter.

Institutional Investors Weigh In On Atrion

Several hedge funds and other institutional investors have recently modified their holdings of ATRI. Penn Mutual Asset Management LLC bought a new stake in shares of Atrion during the fourth quarter valued at about $1,949,000. Citizens Financial Group Inc. RI bought a new stake in shares of Atrion during the fourth quarter valued at about $1,114,000. Boston Trust Walden Corp grew its holdings in shares of Atrion by 4.8% during the fourth quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock worth $13,292,000 after purchasing an additional 1,609 shares in the last quarter. Exchange Traded Concepts LLC purchased a new position in shares of Atrion during the third quarter worth about $333,000. Finally, Jump Financial LLC purchased a new position in shares of Atrion during the fourth quarter worth about $234,000. 66.19% of the stock is currently owned by institutional investors.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.